The HER2 alterations that drive tumor development are HER2 mutations (2–4%), amplification (FISH copy number ≥ 2; 10–20%), and protein overexpression (immunohistochemical score of 2+/3+; 2.4–38%) [122, 123]. This evidence concerns the gene ERBB2 and neoplasm.